DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG
  • Login
  • Products
    • Biopharma
      • Market Assessment
      • Multichannel Engagement Insights
      • Real-World Data
      • Market Access

      • Fingertip Formulary Suite
      • Managed Market Surveyor
      • Account Management Dashboard
      • U.S. Managed Markets Insights
      • Healthbase
      • Market Access Platform
      • Global Market Access Solution
    • Medtech
      • Market Insights
      • Procedure Finder
      • PriceTrack
  • Solutions
    • Solutions
      • Market Sizing and Forecasting
      • Commercial Effectiveness
      • Global Access Solutions
      • Multichannel Engagement Strategy
      • Integrated Patient Journey
      • Understanding Covered Lives
      • Learning Solutions
      • Biotech solutions
      • Medtech Solutions
      • Payer Solutions
      • Provider Solutions
    • Consulting Services
      • Consulting Services
      • HEOR & Value Communication
  • Find A Report
    • Market Assessment
    • Multichannel Engagement
    • Market Access
    • Medtech Insights
  • Events
    • Meet Us at These Events
  • DRG Perspectives
  • About Us
    • Our Company
    • About Clarivate
    • Newsroom
    • Careers
    • Contact us

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
Home › DRG Perspectives › COVID-19 Market Impact Assessment:...
COVID-19 Market Impact Assessment
Imaging
Published on: 20 April 2020
Last updated on: 17 July 2020


DRG’s Medtech Insights (Part of Clarivate) is actively assessing the impact of COVID-19 on all therapy areas and incorporating the impact into reports. This piece contains some therapy-specific highlights based on currently available information.

Imaging
  • Impact Assessment Summary
  • Detailed Impact Information

    • Procedure Volumes and Unit Sales
    • Companies
    • Supply Chain
  • Guidelines/Recommendations

Impact Assessment Summary
Factors Initial Effect Expected 1yr Recovery Comments
Company Sales/Revenue Moderate Moderate Delays in procedures and adverse economic impact will result in facilities delaying the purchase of new systems.
Procedure Volumes Moderate Moderate The majority of imaging procedures have been postponed, except for chest CT and X-ray in COVID-19 patients
ASPs Moderate Moderate Most manufacturers in this space depend on China for raw materials; companies may have to contend with increased production costs until the situation stabilizes.
New Product Launches Weak Weak Early-stage innovation will slow, whereas products in late stages of development should launch as scheduled.
Supply Chain Moderate Moderate Most manufacturers depend on China for raw materials; though supply chain disruptions were observed in Q1, these are not expected to have a substantial impact on large imaging companies.
*General guidance: Weak: 0-10% change in values/timelines; Moderate: 10-20% change in values/timelines; Strong: >20% change in values/timelines. DRG Medtech is developing a robust quantitative framework for our market forecasts; impact metrics shown he re may change in the future to align with those used in the quantitative framework.

Detailed Impact Information
Procedure Volumes and Unit Sales
  • The majority of imaging procedures are performed for screening purposes and therefore are elective in nature. These procedures—including dental imaging, mammography, CT, MRI, general radiography, ultrasound, and nuclear medicine procedures—will be delayed, resulting in declining procedure volumes.
  • Procedure volume declines and the negative economic impact of COVID-19 on healthcare facilities will delay the purchasing of new imaging equipment in the short term.
  • However, CT and general radiography systems play a significant role in the diagnosis and management of COVID-19. As a result, there has been an increase in demand for these two systems, especially portable devices. This has also impacted product innovation; companies are manufacturing portable CT systems that can be easily disinfected to avoid the spread of infection.
Companies
  • Manufacturers like Philips Healthcare, GE Healthcare, and United Imaging Healthcare have increased manufacturing for diagnostic imaging systems.

    • https://www.diagnosticimaging.com/covid-19/vendors-ramp-production-combat-covid-19
  • United Imaging Healthcare has partnered with Sea Box to build temporary CT scanning “rooms” that provide better ventilation compared to conventional CT scanning rooms. Moreover, these temporary rooms will be equipped with high-end CT systems that reduce the scanning times. The surfaces have also been designed to make the disinfection process easier.

    • https://usa.united-imaging.com/united-imaging-releases-information-on-additional-transportable-cts-for-the-us/
Supply Chain
  • Because most of the diagnostic imaging system manufacturers rely upon raw materials shipped from China and South Korea, short-term manufacturing and supply disruptions were observed when lockdowns were implemented in those countries.

Guidelines/Recommendations Links
  • ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection

    • Outlines guidance for imaging patients that are infected or suspected of being infected
  • Guidance from ESR and ESTI

    • Outlines guidance for imaging patients that are infected or suspected of being infected
  • Considerations for medical imaging departments – From ASMIRT Considerations for Imaging Departments

    • Overview of COVID-19 symptoms, epidemiology, and considerations for imaging
  • RSNA COVID-19 Resource Center

    • Contains resources for radiologists
  • Use of chest imaging in COVID-19

    • Guidance for radiologists

MedTech Executive Briefings

A look ahead: Medical aesthetics market recovery in 2021 and beyond

View Now
DRG

Decision Resources Group

DRG is the premier provider of healthcare analytics, data and insight products and services to the world’s leading pharma, biotech and medical technology companies.

Read More

Company

  • About DRG
  • Careers
  • Offices
  • Locations

Resources

  • Sitemap
  • Newsroom
  • Whitepapers
  • Events
  • Reports

Support

  • Client Portal

Social

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Contact Us
  • Privacy & Cookies
  • Term of Use
  • Privacy Center
  • 2020 DR/Decision Resources, LLC
  • Find a Report
  • Linkedin
  • Twitter
  • Contact Us
Thank you for your ebook download,
and live webinar registration.

Don’t forget to attend on Jan. 19!

Close